Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Ucrest Bhd
KLSE:UCREST
|
MY |
|
B
|
Biomimix Inc
OTC:BMMX
|
US |
|
Black Hills Corp
NYSE:BKH
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| FR |
M
|
Maat Pharma SA
PAR:MAAT
|
102.8m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.5B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
361.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -1 220.2% |
| 30th Percentile | 34% |
| Median | 53.6% |
| 70th Percentile | 70.2% |
| Max | 509.6% |
Other Profitability Ratios
Maat Pharma SA
Glance View
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Maat Pharma SA is 61.7%, which is below its 3-year median of 68.2%.
Over the last 3 years, Maat Pharma SA’s Gross Margin has decreased from 78% to 61.7%. During this period, it reached a low of 61.1% on Dec 31, 2024 and a high of 78% on Jun 30, 2022.
